Self-regulating osmotic gastroretentive drug delivery systems
Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane. The rapid swelling of the composition to a size greater than the size of the pyloric sphincter is due to the presence of an osmogen. adequate membrane permeability that provides for fast generation of CO 2 from a gas-generating agent(s), and adequate membrane elasticity that provides for rapid expansion of the membrane. The hydrated core, especially the polyethylene oxide in the push layer, and the permeable elastic membrane with an orifice (1) provide extended release of the active pharmaceutical agent, and (2) maintain the dosage form at a size suitable for gastric retention. The self-regulating composition collapses, or breaks into pieces, after releasing at least about 80% of the drug from the composition.
1. An osmotic, floating gastroretentive dosage form comprising:
a) a multilayer core comprising:
(i) a pull layer containing an active pharmaceutical agent, an acid, and a gas-generating agent, and
(ii) a push layer; and
b) a permeable elastic membrane surrounding the multilayer core, wherein the permeable elastic membrane contains at least one orifice,
wherein the permeable elastic membrane comprises copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride (1:2:0.2) in powder form and at least one plasticizer,
wherein the plasticizer is present in amount of from about 10 wt % to about 20 wt % of the amount of copolymer,
wherein the gas generating agent is present in an amount of from about 10 wt % to about 50 wt % of the pull layer
wherein the orifice in the permeable elastic membrane is in fluid communication with the pull layer, and
wherein the dosage form when coming in contact with a dissolution medium, floats in 30 minutes or less, exhibits about 50% volume gain in about 30 minutes and about 250% volume gain in about 4 hours, maintains the volume gain of about 250% from about 4 hours to about 14 hours, and collapses back to about 150% volume gain in about 18 hours.
2. The dosage form of claim 1 , wherein the at least one plasticizer is selected from the group consisting of triethyl citrate, triacetin, polyethylene glycol, propylene glycol, dibutyl sebacate, and mixtures thereof.
3. The dosage form of claim 1 , wherein the acid is selected from the group consisting of succinic acid, citric acid, acetic acid, malic acid, and tartaric acid, boric acid, and mixtures thereof.
4. The dosage form of claim 1 , wherein the pull layer and the push layer each comprises at least one water-soluble hydrophilic polymer.
5. The dosage form of claim 4 , wherein the water-soluble hydrophilic polymer in the push layer is a polyethylene oxide polymer having an average molecular weight greater than or equal to 600,000 Da.
6. The dosage form of claim 5 , wherein the polyethylene oxide polymer has an average molecular weight of about 700,000 Da, about 800,000 Da, about 900,000 Da, about 1,000,000 Da, about 2,000,000 Da, about 3,000,000 da, about 4,000,000 Da, about 5,000,000 Da, about 6,000,000 Da, about 7,000,000 Da, or intermediate values therein.
7. The dosage form of claim 4 , wherein the water-soluble hydrophilic polymer in the pull layer is a polyethylene oxide polymer having an average molecular weight less than or equal to 1,000,000 Da.
8. The dosage form of claim 7 , wherein the polyethylene oxide polymer has an average molecular weight of about 100,000 Da, about 200,000 Da, about 300,000 Da, about 400,000 Da, about 500,000 Da, about 600,000 Da, about 700,000 Da, about 800,000 Da, about 900,000 Da, or intermediate values therein.
9. The dosage form of claim 4 , wherein the at least one water-soluble hydrophilic polymer in the pull layer is a mixture of two polyethylene oxide polymers having average molecular weights of about 7,000,000 Da and about 200,000 Da, wherein the polyethylene oxide polymers are present in a ratio of from about 1:99 to about 10:90.
10. The dosage form of claim 1 , wherein the gas-generating agent is NaHCO 3 , CaCO 3 , or a mixture thereof.
11. The dosage form of claim 1 , wherein the dosage form provides extended release of the active pharmaceutical agent for a period of at least about 6 hours.
12. The dosage form of claim 1 , wherein the active pharmaceutical agent is a moderately soluble drug.
13. A method for treating a condition that requires extended release of an active pharmaceutical agent in upper gastrointestinal tract, the method comprising administering to a subject, a self-regulating, osmotic, floating gastroretentive dosage form comprising:
a) a multilayer core comprising a pull layer and a push layer, and
b) a permeable elastic membrane surrounding the multilayer core,
wherein the pull layer comprises a polyethylene oxide polymer having an average molecular weight less than or equal to 1,000,000 Da, an active pharmaceutical agent, an acid, and a gas-generating agent,
wherein the push layer comprises a polyethylene oxide polymer having an average molecular weight greater than or equal to about 600,000 Da,
wherein the membrane comprises a plasticizer and a copolymer of ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride (1:2:0.2) in powder form,
wherein the plasticizer is present in an amount of from about 10 wt % to about 20 wt % of the copolymer,
wherein the gas generating agent is present in an amount of from about 10 wt % to about 50 wt % of the pull layer,
wherein the dosage form when coming in contact with a dissolution medium, floats in 30 minutes or less, exhibits about 50% volume gain in about 30 minutes and about 250% volume gain in about 4 hours, maintains the volume gain of about 250% from about 4 hours to about 14 hours, and collapses back to about 150% volume gain in about 18 hours, and
wherein the dosage form provides a stable plasma concentration of the active pharmaceutical agent for at least about 6 hours.